Metabolic Regulators for Hematopoietic Lineage Specification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating hematopoietic cells from differentiating source cells, such as induced pluripotent stem cells (iPS) and hemogenic endothelial cells, lack efficient mechanisms to direct metabolic pathways for specific hematopoietic lineage specification.
Innovation Solution
The method involves treating source cells with metabolic regulators that direct the cells to preferentially use glycolysis or oxidative phosphorylation, thereby generating GPA+ erythroid cells or CD45+ non-erythroid cells. Specific metabolic regulators include molecules that block or promote pyruvate metabolism, such as UK5099, 1-AA, and DCA, which inhibit mitochondrial pyruvate carrier and pyruvate dehydrogenase complex, respectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If metabolic pathways are not regulated, then hematopoietic cells can differentiate into multiple lineages, but lineage specification efficiency is low
Solution Approach 1:
The patent applies parameter changes by modulating metabolic parameters (glycolysis vs oxidative phosphorylation) to control hematopoietic lineage specification. By adjusting metabolic regulators and their concentrations, the method achieves efficient directional differentiation while maintaining the ability to produce different lineages through parameter adjustment.
Solution Approach 2:
The patent implements local quality by creating distinct metabolic microenvironments for differentiating cells. Specific metabolic regulators are applied to establish localized metabolic states that direct lineage commitment, allowing different regions or conditions to produce different hematopoietic lineages with high efficiency.
2Ease of operation
If conventional differentiation methods are used, then multiple hematopoietic lineages can be generated, but control over specific lineage output is insufficient
Solution Approach 1:
The patent uses metabolic regulators as intermediary molecules to transmit control signals from the external environment to the differentiating cells. These intermediaries (metabolic regulators) mediate the control of lineage specification by modulating metabolic pathways, providing precise control without requiring complex physical devices.
Solution Approach 2:
The patent replaces mechanical or physical control systems with biochemical metabolic regulation. Instead of using complex mechanical devices to control differentiation, the method uses small molecule metabolic regulators to achieve precise lineage control through biochemical pathway modulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively directs the differentiation of source cells into specific hematopoietic lineages by modulating metabolic pathways, enhancing our understanding and control over hematopoietic cell generation for therapeutic applications.
Implementation Method 1
treating the source cell with a metabolic regulator that directs the source cell to preferentially use glycolysis or oxidative phosphorylation
Implementation Method 2
treating the source cell with a metabolic regulator that directs the source cell to preferentially use glycolysis or oxidative phosphorylation
Implementation Method 3
Specific metabolic regulators include molecules that block or promote pyruvate metabolism, such as UK5099, 1-AA, and DCA
Data Source
AI summary
A method of generating a hematopoietic cell, including providing a source cell and treating the source cell with a metabolic regulator that directs the source cell to preferentially use glycolysis or oxidative phosphorylation and/or cholesterol biosynthesis, wherein the source cell is differentiated into a GPA+ erythroid cell or a CD45+ non-erythroid cell. In some examples, the source cell is selected from the group consisting of a hemogenic endothelial (HE) cell, a iPS cell such as a differentiating iPS cell, a cell directly reprogrammed to a known pre-cursor of a hematopoietic cell, a cell directly reprogrammed to a hematopoietic cell or precursor of a hematopoietic cell, a reprogrammed cell that is subsequently further reprogrammed to a hematopoietic cell or precursor of a hematopoietic cell, an adult hematopoietic cell derived from bone marrow or mobilized peripheral blood and a neonatal hematopoietic cell derived from cord blood or prenatal tissue (e.g. placenta). Some examples involve metabolically regulating a lipid biosynthesis pathway with an inhibitor of the lipid biosynthesis pathway or metabolically regulating a histone acetylation pathway with an inhibitor of the histone acetylation pathway.